SCHEDULE 13G: Schonfeld Strategic Advisors Discloses 5.22% Stake in Skye Bioscience, Inc.
Beneficial Ownership Report
Schonfeld Strategic Advisors LLC has reported a 5.22% beneficial ownership stake in Skye Bioscience, Inc., holding 1,617,697 shares of common stock.
Summary
- Schonfeld Strategic Advisors LLC, an investment adviser, has filed a Schedule 13G indicating beneficial ownership of Skye Bioscience, Inc. common stock.
- The firm beneficially owns 1,617,697 shares of Skye Bioscience, Inc. common stock.
- This ownership represents 5.22% of the issuer's outstanding common stock.
- The percentage is calculated based on 30,984,358 shares of common stock outstanding as of May 6, 2025, as reported in Skye Bioscience's Form 10-Q filed on May 8, 2025.
- Schonfeld Strategic Advisors LLC holds sole voting power and sole dispositive power over all 1,617,697 shares.
- The securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.
Sentiment
Score: 6
Explanation: The sentiment is slightly positive as it indicates a significant institutional investor has taken a stake, which can be viewed as a vote of confidence. However, the filing itself is purely factual and does not contain forward-looking statements or performance data.
Positives
- A significant institutional investment firm, Schonfeld Strategic Advisors LLC, has taken a 5.22% stake in Skye Bioscience, Inc., indicating potential confidence in the company.
Negatives
- No negative information is disclosed in this beneficial ownership report.
Risks
- No specific risks related to Skye Bioscience, Inc. are detailed in this Schedule 13G filing, as it primarily reports ownership.
Future Outlook
NA
Industry Context
This filing indicates that a significant investment adviser, Schonfeld Strategic Advisors LLC, has taken a notable stake in Skye Bioscience, Inc. This type of institutional investment can signal increased market interest or confidence in the biotechnology or pharmaceutical sector, particularly for companies like Skye Bioscience that may be involved in drug development or related research.
Stakeholder Impact
- Shareholders: The disclosure of a new significant institutional investor may positively influence market perception and potentially the share price.
Key Dates
| Date | Description |
|---|---|
| 03/31/2025 | Date of event which requires filing of this statement. |
| 05/06/2025 | Date as of which 30,984,358 shares of common stock were outstanding, used for percentage calculation. |
| 05/08/2025 | Date Skye Bioscience, Inc. filed its Quarterly Report on Form 10-Q, which provided the shares outstanding figure. |
| 05/15/2025 | Date the Schedule 13G was signed by Schonfeld Strategic Advisors LLC. |
Keywords
Skye Bioscience, Schonfeld Strategic Advisors, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investor, SEC Filing, Investment Adviser
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.